You are here

Share:

Vectors to Increase Production Efficiency of Inducible Pluripotent Stem Cell (iPSC)

Summary
This invention describes the discovery that specific p53 isoform increase the number of inducible pluripotent stem cells (iPS). It is known that the activity of p53 regulates the self-renewal and pluripotency of normal and cancer stem cells, and also affects re-programming efficiency of iPS cells. This p53 isoform-based technology provides a more natural process of increasing iPS cell production than previous methods of decreasing p53. NCI seeks licensees for this technology.
NIH Reference Number
E-239-2010
Product Type
Keywords
  • cancer therapy, regenerative medicine, p53, iPS cells, Harris
Collaboration Opportunity
This invention is available for licensing and co-development.
Contact
Description of Technology

Researchers at the National Cancer Institute discovered that modulating a specific p53 isoform increases the number of inducible pluripotent stem cells (iPS) that can be obtained from cells that are being re-programmed to obtain pluripotent cells. It is known that the activity of p53 regulates the self-renewal and pluripotency of normal and cancer stem cells, and also affects re-programming efficiency of iPS cells. This p53 isoform-based technology provides a more natural process of increasing iPS cell production than previous methods of decreasing p53.

The National Cancer Institute, Laboratory of Human Carcinogenesis, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Retroviral and Lentiviral Vectors.

Potential Commercial Applications
  • Stem cell-based regenerative medicine
  • Cancer therapeutic that targets cancer stem cells
Competitive Advantages
  • The retroviral and lentiviral vectors in this invention allow more selective control of p53 activities than siRNA or mutant p53 methods.
Development Stage
Patent Status
  • Foreign Filed: Canada - Patent Application 2812300, Filed 15 Mar 2013
  • Foreign Issued: European - Patent Number 2622065, Issued 07 Sep 2016
  • Foreign Issued: Germany - Patent Number 602011030.80005, Issued 07 Sep 2016
  • Foreign Issued: France - Patent Number 2622065, Issued 07 Sep 2016
  • Foreign Issued: United Kingdom - Patent Number 2622065, Issued 07 Sep 2016
Related Technologies
Therapeutic Area
Updated
Tuesday, March 20, 2018